We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Eagle Pharmaceuticals Inc | NASDAQ:EGRX | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.01 | 0.23% | 4.41 | 4.10 | 4.47 | 4.6023 | 4.24 | 4.42 | 51,307 | 23:30:10 |
Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle” or “the Company”) today announced that Scott Tarriff, Chief Executive Officer, and Pete Meyers, Chief Financial Officer, will present at the 29th Annual Piper Jaffray Healthcare Conference as follows:
Date: Wednesday, November 29, 2017 Time: 11:30 a.m. Eastern Standard Time Location: Lotte New York Palace, New YorkWebcast:
https://event.webcasts.com/starthere.jsp?ei=1171368&tp_key=fc44350be5
The presentation will be webcast live at the aforementioned time, and archived for 30 days thereafter, via the Company’s website at www.eagleus.com, under the Investors Section.
About Eagle Pharmaceuticals, Inc.
Eagle is a specialty pharmaceutical company focused on developing and commercializing injectable products that address the shortcomings, as identified by physicians, pharmacists and other stakeholders, of existing commercially successful injectable products. Eagle’s strategy is to utilize the FDA's 505(b)(2) regulatory pathway. Additional information is available on the Company’s website at www.eagleus.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171120005649/en/
Investor Relations for Eagle Pharmaceuticals, Inc:Lisa M. Wilson, 212-452-2793lwilson@insitecony.com
1 Year Eagle Pharmaceuticals Chart |
1 Month Eagle Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions